Two programs. One quantum-enhanced design platform. Eight to sixteen weeks from sequence to in-vitro PoC†; in-vivo timeline partner-lab dependent.
● Live in your browser — real ESMFold + Mol*, no account or login required.
† Design targets and in-silico / modeled figures — not yet demonstrated in vivo. Library size is current. Measured results publish on Benchmarks as programs mature.
Quantum-enhanced AI fused with a wet-lab data flywheel. Each layer feeds the next; each candidate carries a cryptographically anchored evidence trail.
Multi-specific antibody programs in oncology — each on the same eight-to-sixteen-week path from sequence to in-vitro PoC; in-vivo schedule partner-lab dependent.
EpCAM-positive epithelial tumors. Tumor-targeted T-cell engagement with 4-1BB costimulation designed to mitigate T-cell exhaustion from sustained CD3 engagement; conditional costimulation mechanism requires functional validation. In-licensed program.
EpCAM-positive epithelial tumors. Tumor-localized 4-1BB costimulation (no CD3) designed to concentrate agonism in EpCAM-positive tissue while limiting systemic exposure; a human serum albumin (HSA) module extends half-life. Mechanism requires functional validation. In-licensed program.
On raw folding accuracy, AlphaFold 3 and Chai-1 set the bar; NOVA-3 wraps them. Our differentiation is upstream — multi-specific composability via the Module Library — and downstream — quantum-corrected refinement, cryptographic provenance, and a wet-lab flywheel. Every result is reproducible from an Evidence Bundle.
Curated, schema-typed Module Library across binders / linkers / hinges / effectors. Folding models (Chai-1, Boltz-2) predict a structure from a sequence; NOVA-3 composes a multi-arm molecule from validated parts, then wraps those folders to evaluate it. Different layer of the stack — we compose, they predict.
VQE active-space corrections for the hardest, strongly-correlated chemistry — validated on simulators today, with hardware access in progress; the hardware fraction of every job is reported. No claim of demonstrated quantum advantage in ground-state chemistry — we engage with the open question rather than assert it.
Every candidate ships an OpenTimestamps-anchored Evidence Bundle. You don't have to take our word: paste any bundle's SHA-256 root into the verifier and confirm the Bitcoin anchor and invention date independently. Verify a bundle →
QAI Labs Ltd. is a Delaware corporation headquartered in Sugar Land, Texas, building at the intersection of pharma business development, quantum hardware partnerships, and multi-specific antibody engineering — with collaborators across North America, Europe, and Asia-Pacific.
Drug developer and entrepreneur with a background in therapeutic antibody engineering at Medarex and Bristol-Myers Squibb, where he contributed to programs advancing through Phase I/II. At QAI Labs he leads company strategy, platform commercialization, and partnerships — including the IBM Quantum and Quantinuum integrations. Brings pharma-grade evidentiary discipline to every platform claim.
Physician-scientist and co-inventor of the XFab multi-specific antibody platform, whose IP is owned by a third-party licensor and licensed to QAI Labs (patent assignments in progress; structure available under NDA). Brings direct experience advancing multi-specific antibody candidates through preclinical and early clinical development. Leads program strategy and platform architecture — each program is evaluated from inception against what a clinical development team would require.
Computational scientist and co-inventor of the XFab quantum-augmented molecular simulation platform, owned by a third-party licensor and licensed to QAI Labs (patent assignments in progress). Architects and operates the NOVA-3 quantum compute layer — VQE active-space corrections, QAOA assignment optimization, and the hardware interface to IBM Quantum and Quantinuum. Reports hardware fraction on every job; makes no claim of demonstrated quantum advantage.
Pharma BD, partner labs, and quantum hardware collaborations. The first conversation usually starts with a program walkthrough and an Evidence Bundle review. Or submit a target antigen below and we'll scope a design in 48 hours.